BR9907203A - "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " - Google Patents
"composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. "Info
- Publication number
- BR9907203A BR9907203A BR9907203-3A BR9907203A BR9907203A BR 9907203 A BR9907203 A BR 9907203A BR 9907203 A BR9907203 A BR 9907203A BR 9907203 A BR9907203 A BR 9907203A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- compound
- adhd
- cocaine
- migraine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9801230.5A GB9801230D0 (en) | 1998-01-21 | 1998-01-21 | Pharmaceutically active morpholinol |
| US7218098P | 1998-01-22 | 1998-01-22 | |
| PCT/US1999/001134 WO1999037305A1 (en) | 1998-01-21 | 1999-01-20 | Pharmaceutically active morpholinol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9907203A true BR9907203A (pt) | 2000-10-17 |
Family
ID=26312986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9907203-3A BR9907203A (pt) | 1998-01-21 | 1999-01-20 | "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6274579B1 (https=) |
| EP (2) | EP1047428B1 (https=) |
| JP (1) | JP2002501025A (https=) |
| KR (1) | KR100568063B1 (https=) |
| CN (2) | CN1203858C (https=) |
| AP (1) | AP1229A (https=) |
| AT (1) | ATE365042T1 (https=) |
| AU (1) | AU755536B2 (https=) |
| BR (1) | BR9907203A (https=) |
| CA (1) | CA2318268A1 (https=) |
| CY (1) | CY1106828T1 (https=) |
| DE (1) | DE69936335T2 (https=) |
| DK (1) | DK1047428T3 (https=) |
| EA (1) | EA002410B1 (https=) |
| EE (1) | EE04452B1 (https=) |
| ES (1) | ES2288012T3 (https=) |
| HR (2) | HRP20051024A2 (https=) |
| HU (1) | HUP0100900A3 (https=) |
| ID (1) | ID26334A (https=) |
| IL (2) | IL161942A0 (https=) |
| IS (1) | IS2494B (https=) |
| NO (2) | NO326878B1 (https=) |
| NZ (3) | NZ520349A (https=) |
| PL (1) | PL193622B1 (https=) |
| PT (1) | PT1047428E (https=) |
| SG (1) | SG115489A1 (https=) |
| SK (1) | SK10912000A3 (https=) |
| TR (1) | TR200002126T2 (https=) |
| WO (1) | WO1999037305A1 (https=) |
| YU (1) | YU67102A (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098206B2 (en) * | 1998-01-21 | 2006-08-29 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6998400B2 (en) | 1998-01-22 | 2006-02-14 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| AU2349999A (en) * | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmacological uses of pure (+) -bupropion |
| US6855820B2 (en) | 1999-01-20 | 2005-02-15 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6734213B2 (en) | 1999-01-20 | 2004-05-11 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| EP1220673A2 (en) * | 1999-10-13 | 2002-07-10 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
| GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
| US7145649B2 (en) * | 2000-12-21 | 2006-12-05 | Brasscorp Limited | Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing |
| US6979104B2 (en) | 2001-12-31 | 2005-12-27 | R.J. Doran & Co. LTD | LED inspection lamp |
| EP3173082A1 (en) | 2002-05-17 | 2017-05-31 | Duke University | Method for treating obesity |
| US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| GB0219687D0 (en) * | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| WO2004017977A2 (en) * | 2002-08-23 | 2004-03-04 | Eli Lilly And Company | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors |
| HUE034290T2 (en) | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
| US20070093486A1 (en) * | 2003-10-27 | 2007-04-26 | Smith Kline Beecham Corporation ,Corporation | Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof |
| GB0325055D0 (en) * | 2003-10-27 | 2003-12-03 | Smithkline Beecham Corp | New process |
| GB0326148D0 (en) * | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
| GB0327195D0 (en) * | 2003-11-21 | 2003-12-24 | Smithkline Beecham Corp | Novel use |
| GB0327619D0 (en) * | 2003-11-27 | 2003-12-31 | Smithkline Beecham Corp | New use |
| US7429580B2 (en) * | 2004-01-13 | 2008-09-30 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
| US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
| RU2006139930A (ru) * | 2004-05-03 | 2008-06-10 | Дюк Юниверсити (Сша/Сша) (Us) | Составы для содействия снижению веса |
| FI117283B (fi) | 2005-02-04 | 2006-08-31 | Kone Corp | Hissijärjestelmä |
| CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| CA2635261A1 (en) * | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| KR20170077291A (ko) | 2006-11-09 | 2017-07-05 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
| TWI609702B (zh) | 2006-11-09 | 2018-01-01 | 歐瑞根治療有限公司 | 層狀醫藥調配物 |
| US20090075994A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched radafaxine |
| JP2011521973A (ja) | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
| EP2419400A1 (en) | 2009-04-15 | 2012-02-22 | Research Triangle Institute | Monoamine reuptake inhibitors |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| JP2013526583A (ja) | 2010-05-21 | 2013-06-24 | リサーチ・トライアングル・インスティチュート | フェニルモルホリンおよびその類似体 |
| CA2800219C (en) | 2010-05-21 | 2019-03-12 | Research Triangle Institute | 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence |
| US9510405B2 (en) | 2011-06-30 | 2016-11-29 | Schneider Electric Industries Sas | Dual power SMPS for a modular lighting system |
| CN102670617B (zh) * | 2012-04-13 | 2013-03-20 | 湖南大学 | 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用 |
| LT3730132T (lt) | 2012-06-06 | 2022-08-25 | Nalpropion Pharmaceuticals Llc | Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde |
| CN105949142B (zh) * | 2016-05-21 | 2018-03-27 | 南华大学 | 具有抗抑郁活性的单一手性化合物及其制备方法和应用 |
| RU2763728C1 (ru) * | 2021-06-17 | 2021-12-30 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US170430A (en) * | 1875-11-30 | Improvement in furnaces for heating steel in tempering | ||
| GB8417170D0 (en) * | 1984-07-05 | 1984-08-08 | Wellcome Found | Heterocyclic pharmaceutical compounds |
| GB9108629D0 (en) | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
-
1999
- 1999-01-20 PL PL99342012A patent/PL193622B1/pl not_active IP Right Cessation
- 1999-01-20 US US09/233,531 patent/US6274579B1/en not_active Expired - Fee Related
- 1999-01-20 AU AU23280/99A patent/AU755536B2/en not_active Ceased
- 1999-01-20 EP EP99903200A patent/EP1047428B1/en not_active Expired - Lifetime
- 1999-01-20 SK SK1091-2000A patent/SK10912000A3/sk unknown
- 1999-01-20 WO PCT/US1999/001134 patent/WO1999037305A1/en not_active Ceased
- 1999-01-20 IL IL16194299A patent/IL161942A0/xx unknown
- 1999-01-20 IL IL13734699A patent/IL137346A0/xx not_active IP Right Cessation
- 1999-01-20 NZ NZ520349A patent/NZ520349A/en unknown
- 1999-01-20 CA CA002318268A patent/CA2318268A1/en not_active Abandoned
- 1999-01-20 HR HR20051024A patent/HRP20051024A2/hr not_active Application Discontinuation
- 1999-01-20 ES ES99903200T patent/ES2288012T3/es not_active Expired - Lifetime
- 1999-01-20 CN CNB998042706A patent/CN1203858C/zh not_active Expired - Fee Related
- 1999-01-20 JP JP2000528287A patent/JP2002501025A/ja active Pending
- 1999-01-20 NZ NZ505809A patent/NZ505809A/xx unknown
- 1999-01-20 SG SG200204411A patent/SG115489A1/en unknown
- 1999-01-20 PT PT99903200T patent/PT1047428E/pt unknown
- 1999-01-20 NZ NZ529316A patent/NZ529316A/en unknown
- 1999-01-20 DK DK99903200T patent/DK1047428T3/da active
- 1999-01-20 EP EP07110283A patent/EP1829544A1/en not_active Withdrawn
- 1999-01-20 DE DE69936335T patent/DE69936335T2/de not_active Expired - Lifetime
- 1999-01-20 HR HR20000494A patent/HRP20000494B1/xx not_active IP Right Cessation
- 1999-01-20 BR BR9907203-3A patent/BR9907203A/pt not_active Application Discontinuation
- 1999-01-20 AP APAP/P/2000/001869A patent/AP1229A/en active
- 1999-01-20 HU HU0100900A patent/HUP0100900A3/hu unknown
- 1999-01-20 CN CNB2004100085595A patent/CN1255389C/zh not_active Expired - Fee Related
- 1999-01-20 EE EEP200000438A patent/EE04452B1/xx not_active IP Right Cessation
- 1999-01-20 ID IDW20001597A patent/ID26334A/id unknown
- 1999-01-20 AT AT99903200T patent/ATE365042T1/de active
- 1999-01-20 KR KR1020007007996A patent/KR100568063B1/ko not_active Expired - Fee Related
- 1999-01-20 TR TR2000/02126T patent/TR200002126T2/xx unknown
- 1999-01-20 EA EA200000691A patent/EA002410B1/ru not_active IP Right Cessation
-
2000
- 2000-07-20 NO NO20003721A patent/NO326878B1/no not_active IP Right Cessation
- 2000-07-20 IS IS5568A patent/IS2494B/is unknown
-
2001
- 2001-06-22 US US09/886,391 patent/US6391875B2/en not_active Expired - Fee Related
-
2002
- 2002-09-06 YU YU67102A patent/YU67102A/sh unknown
-
2007
- 2007-08-31 CY CY20071101117T patent/CY1106828T1/el unknown
-
2008
- 2008-08-14 NO NO20083529A patent/NO20083529L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9907203A (pt) | "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| ATE292982T1 (de) | Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu- opioidanagonisten und eines kappa - 2- opioidanagonisten | |
| BR0110487A (pt) | Composição farmacêutica e método de tratamento de doenças de disfunção cognitiva em um mamìfero | |
| JP2002501025A5 (https=) | ||
| ATE232384T1 (de) | Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE60222137D1 (de) | Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen | |
| DE60134453D1 (de) | Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten | |
| HUP9800794A2 (hu) | (S)-oxi-butinin és (S)-dezetil-oxi-butinin alkalmazása vizelet inkontinencia kezelésére alkalmazható gyógyszerkészítmények előállítására és a vegyületek előállítása | |
| BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
| IL206829A0 (en) | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit | |
| BR0103169A (pt) | Composição farmacêutica para o tratamento do distúrbio de hiperatividade de déficit de atenção (adhd) | |
| HUP0401484A2 (hu) | BIBN4096 alkalmazása kombinációban más migrénellenes szerekkel migrén kezelésére és a kombinációt tartalmazó gyógyszerkészítmények | |
| BR9508841A (pt) | Utilização do 2,4-diamino pirimidina 3-óxido ou de um de seus sais no tratamento das desordens da maturaç o e da estruturação do colágeno | |
| ATE301462T1 (de) | Verwendung von reboxetine zur behandlung neuropsychiatrischer beschwerden | |
| HUP0000110A2 (hu) | Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények | |
| ATE235237T1 (de) | Sertralin zur behandlung von post-myocard-infarkt-patienten | |
| BR9406865A (pt) | Uso de um sal farmaceuticamente aceitável de ropivacaina na fabricaçao de um produto farmaceutico processo para o tratamento de uma pessoa necessitando de alivio da dor e preparaçao farmaceutica | |
| ATE331523T1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| YU46300A (sh) | Farmaceutski aktivni morfolinol | |
| BR0116724A (pt) | Composto, método de tratamento de um distúrbio neurológico ou de uma doença neurodegenerativa, método de tratamento de dor, composição farmacêutica, uso de um composto, e, processos para a preparação e para a sìntese de um composto | |
| BR0005039A (pt) | Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca | |
| DE602004025001D1 (de) | Verbindungen zur behandlung von neuropathischen schmerzen und migräne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT. CL 7: C07D265/32; A61K31/5375; A61P25/24 Ipc: C07D 265/32 (2007.10), A61K 31/5375 (2007.10), A61 |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS. 8O,11, 13 E 25 DA LPI |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL: C07D 265/32, A61K 31/5375, A61P 25/34 Ipc: C07D 265/32 (2008.04), A61K 31/5375 (2008.04), A61 |